On December 4, 2017 Radius Health, Inc. (Nasdaq:RDUS), reported that it will present data from multiple clinical and pre-clinical studies of elacestrant, an oral selective estrogen degrader, in ER-positive breast cancer at the San Antonio Breast Cancer Symposium Meeting December 5-9, 2017 at the Henry B. Gonzalez Convention Center in San Antonio, Texas (Press release, Radius, DEC 4, 2017, View Source [SID1234522365]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the abstracts related to elacestrant are below:

Abstract Title: Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients
Poster Session 1 (P1-10-04)
Session Title: Treatment: New Drugs and Treatment Strategies
Session Date: Wednesday, 12/6/2017
Session Time: 5:00 PM — 7:00 PM
Location: Hall 1

Abstract Title: Elacestrant, oral selective estrogen receptor degrader (SERD) in patients with ER positive (ER+)/HER2- advanced breast cancer: Updated phase 1 efficacy, safety and pharmacodynamic results
Spotlight Session 5 (PD5-08)
Session Title: Endocrine Therapy: SERDS for metastatic ER+ breast cancer
Session Date: Thursday, 12/7/2017
Session Time: 5:00 PM — 7:00 PM
Location: Ballroom 1&2 – 3rd Level

Abstract Title: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
Poster Session 4 (P4-04-09)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: Friday, 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstract Title: Anti-tumor activity of elacestrant (RAD1901) in combination with alpelisib (BYL-719) in patient-derived xenograft models of ER+ breast cancer
Poster Session 4 (P4-04-14)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstract Title: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
Poster Session 4 (P4-04-17)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstracts for the posters can be found on the SABCS website at View Source

Webcast Information

Radius will host an investor meeting and webcast on Thursday, December 7th to highlight the elacestrant data presented at SABCS and provide a company update at 8:00 p.m. CT / 9:00 p.m. ET.

The live webcast titled "Oncology Program Update from San Antonio Breast Cancer Symposium — 2017" will be available at View Source or by visiting the Investors section of Radius’ website at View Source

A replay of the webcast will be archived on Radius’ website for 30 days following the presentation.

About Elacestrant (RAD1901)
Elacestrant is a selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once daily oral treatment for hormone-receptor positive breast cancer. Elacestrant is currently being investigated for potential use in women with advanced estrogen receptor positive, HER2 negative, breast cancer, the most common form of the disease. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.

Additional information on the clinical trial program of elacestrant (RAD1901) is available on www.clinicaltrials.gov.